Products for Research Use Only
RegisterLogin

ETN029

CAT: 0804-HY-W1126504-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-W1126504-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
ETN029 is a DLL3 ligand. ETN029 labeled with 225Ac has dose-dependent cytotoxicity in SCLC, NEPC and metastatic melanoma cells and increases the phosphorylation of H2AX expression. ETN029 labeled with 177Lu shows rapid uptake persistent tumor retention and favorable tumor-to-kidney ratio. ETN029 can be used for cancers like SCLC and NEPC imaging and research[1].
CAS Number
3066864-32-9
UNSPSC
12352005
Target
Notch
Related Pathways
Neuronal Signaling; Stem Cell/Wnt
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Purity
99.91
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
CC(N[C@@H](CC1=CNC2=C1C=CC=C2)C(N[C@H](C(N([C@H](C(N[C@@H]3C(N[C@@H](CC4CCN(CC(O)=O)CC4)C(N[C@@H](CC(N)=O)C(N[C@@H](CC5=CC=C6C=CC=CC6=C5)C(N[C@@H](CCCCNC(CN7CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC7)=O)C(N[C@@H](CC(O)=O)C(N[C@H](C(N[C@H](C(N8CCC[C@H]8C(N)=O)=O)CC9=CNC%10=C9C=CC=C%10)=O)CSCSC3)=O)=O)=O)=O)=O)=O)=O)CC(C)(C)C)C)=O)[C@@H](C)O)=O)=O
Molecular Formula
C101H140N22O26S2
Molecular Weight
2142.45
References & Citations
[1]Chunhui Huang, et al. ETN029: Discovery and development of a DLL3-targeting radioligand therapy for the treatment of SCLC and beyond. ACS. 2025 Aug 20.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture and light)
Scientific Category
Peptides
Clinical Information
No Development Reported

Related Products

CatalogName
HY-RS04560ETNK2 Human Pre-designed siRNA Set A

Alternative Products

CatalogName
T210498-01ETN029

Popular Products